This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Add Alkermes (ALKS) to Your Portfolio
by Zacks Equity Research
Alkermes (ALKS), a top-ranked stock, has a diverse portfolio of neurological therapies. Its proprietary products are witnessing incremental sales.
Novartis (NVS) to Divest Xiidra, SAF312 to Streamline Focus
by Zacks Equity Research
Novartis (NVS) signs a deal to divest Xiidra and SAF312 (libvatrep) to Bausch + Lomb for $2.5 billion.
Roche (RHHBY) Announces Positive Long-Term Data on SMA Drug
by Zacks Equity Research
Roche's (RHHBY) SMA drug Evrysdi maintains its efficacy and safety profile in children with type 1 SMA after four years of treatment.
Aurinia (AUPH) Up on Paving the Way for a Potential Buyout
by Zacks Equity Research
Aurinia (AUPH) surges as management decides to explore strategic business options, including potential sale or a merger.
Immunome (IMNM) Surges on Merger Agreement With Morphimmune
by Zacks Equity Research
Immunome's (IMNM) shares rise following its announcement to merge with Morphimmune. The synergy will help strengthen the development of oncology therapies.
Bristol Myers' (BMY) Opdivo With Chemo Gets EC Nod for NSCLC
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gains European Commission approval for neoadjuvant treatment of non-small cell lung cancer, offering new hope for reducing recurrence risk.
Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly
by Zacks Equity Research
Eli Lilly (LLY) is set to acquire Sigilon (SGTX) for $14.92 per share, in cash, along with a contingent value right of $111.64 per share.
Esperion (ESPR) to Expand Nilemdo and Nustendi Label in Europe
by Zacks Equity Research
Esperion (ESPR) files type II(a) variation application for expanded use of Nilemdo and Nustendi in Europe to reduce cardiovascular risk.
Axsome (AXSM) Down on Public Offering of Common Stock
by Zacks Equity Research
Axsome (AXSM) is set to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.
Sanofi (SNY) Atopic Dermatitis Drug Meets Goals in Phase II Study
by Zacks Equity Research
Sanofi's (SNY) phase II study, investigating amlitelimab for moderate-to-severe atopic dermatitis in adults, meets the primary endpoint.
Amicus (FOLD) Gets Approval in Europe for Pompe Disease Drug
by Zacks Equity Research
Amicus (FOLD) receives approval for Opfolda (miglustat) from the European Commission to treat the adult late-onset Pompe disease.
Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint
by Zacks Equity Research
Agios' (AGIO) mid-stage, label expansion study of mitapivat meets its primary endpoint. The data from the study supports AGIO's decision to proceed with the phase III portion of the investigation.
FibroGen (FGEN) Plunges on Failure of Late-Stage IPF Study
by Zacks Equity Research
FibroGen (FGEN) plummets on yet another pipeline setback. The phase III study, ZEPHYRUS-1, evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis fails to meet goals.
Bristol Myers (BMY) Heart Drug Camzyos Wins EC Approval
by Zacks Equity Research
Bristol Myers (BMY) receives EC approval for Camzyos for treating symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients.
NVS or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
Pfizer (PFE) Stock Down on Halting Development of Obesity Drug
by Zacks Equity Research
Shares of Pfizer's (PFE) fell 3.7% on Monday after management's decision to terminate the development of an experimental obesity pill following concerns over liver safety.
GSK's (GSK) Gonorrhoea Vaccine Gets FDA Fast Track Tag
by Zacks Equity Research
The FDA grants fast-track designation to GSK's investigational gonorrhoeae vaccine candidate. The grant enables GSK to seek expedited review for a potential FDA filing of the vaccine.
Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Gilead's breast cancer drug Trodelvy gets positive CHMP opinion for a second indication in Europe.
AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval
by Zacks Equity Research
AbbVie (ABBV) receives a positive recommendation from the European Union's medicinal products committee for the approval of its migraine treatment candidate, atogepant.
Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data
by Zacks Equity Research
Novo Nordisk (NVO) announces encouraging new data from its late-stage ONWARDS 1 and 3 studies on once-weekly basal insulin icodec against once-daily comparators at 52 and 26 weeks, respectively.
Amylyx (AMLX) Down on Negative CHMP Opinion for ALS candidate
by Zacks Equity Research
Amylyx's (AMLX) shares plunge on getting a negative opinion from the Committee for Medicinal Products for Human Use for the marketing authorization of AMX0035, used to treat amyotrophic lateral sclerosis.
Pfizer's (PFE) Litfulo Receives FDA Nod for Alopecia Areata
by Zacks Equity Research
Pfizer's (PFE) Litfulo becomes the first kinase inhibitor approved for treating severe alopecia areata in adolescents, following FDA's approval.
Zacks.com featured highlights Toll Brothers, Walmart, Caterpillar, W.W. Grainger and Novartis
by Zacks Equity Research
Toll Brothers, Walmart, Caterpillar, W.W. Grainger and Novartis have been highlighted in this Screen of The Week article.
Gilead Sciences (GILD) Announces Positive HDV Treatment Data
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announces data on Hepcludex that reinforces the potential of bulevirtide as an effective and well-tolerated treatment for chronic HDV after 96 weeks.
Sarepta (SRPT) Gets FDA's Accelerated Nod for DMD Gene Therapy
by Zacks Equity Research
Following FDA???s approval, Sarepta's (SRPT) Elevidys becomes the first gene therapy for treating DMD.